$EVOK
Evoke Pharma Inc

2015 Q1 Form 10-K Financial Statement

#000156459015001287 Filed on March 04, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2014 Q4 2014 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.030M $740.0K $620.0K
YoY Change -3.74% -21.28% 785.71%
% of Gross Profit
Research & Development $2.420M $2.176M $2.875M
YoY Change 30.66% 241.97% 2097.22%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $3.445M $2.176M $3.492M
YoY Change 17.88% 241.97% 1616.55%
Operating Profit -$3.445M -$3.492M
YoY Change 17.88% 1616.55%
Interest Expense $77.05K -$10.00K -$60.00K
YoY Change 108.55% -75.0% 50.0%
% of Operating Profit
Other Income/Expense, Net -$75.53K $0.00 -$55.18K
YoY Change 129.64% 51.38%
Pretax Income -$3.520M -$2.920M -$3.550M
YoY Change 18.92% 80.25% 1379.17%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$3.521M -$2.920M -$3.547M
YoY Change 19.13% 80.6% 1378.73%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$577.0K -$482.6K -$588.7K
COMMON SHARES
Basic Shares Outstanding 6.137M 6.112M 6.100M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q1 2014 Q4 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.69M $14.16M $16.05M
YoY Change -46.47% -41.49% 1428.57%
Cash & Equivalents $11.69M $14.16M $16.05M
Short-Term Investments
Other Short-Term Assets $23.62K $161.4K $890.0K
YoY Change -86.88% -29.81%
Inventory
Prepaid Expenses $931.5K $888.9K
Receivables
Other Receivables
Total Short-Term Assets $12.57M $15.25M $16.93M
YoY Change -42.88% -37.58% 1512.83%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $47.12K $53.02K $88.46K
YoY Change -91.52% -90.45% -88.05%
Total Long-Term Assets $47.12K $53.02K $88.46K
YoY Change -91.52% -90.45% -88.05%
TOTAL ASSETS
Total Short-Term Assets $12.57M $15.25M $16.93M
Total Long-Term Assets $47.12K $53.02K $88.46K
Total Assets $12.62M $15.30M $17.02M
YoY Change -44.07% -38.76% 851.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.350M $1.010M $1.300M
YoY Change 20.54% 260.71% 116.67%
Accrued Expenses $420.0K $700.0K $540.0K
YoY Change 7.69% 25.0% 184.21%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $712.9K $126.8K $0.00
YoY Change -50.58% -91.21% -100.0%
Total Short-Term Liabilities $2.500M $1.848M $1.837M
YoY Change -15.09% -19.12% 7.43%
LONG-TERM LIABILITIES
Long-Term Debt $3.688M $4.196M $0.00
YoY Change 218.86% 177.64% -100.0%
Other Long-Term Liabilities $20.00K
YoY Change
Total Long-Term Liabilities $3.688M $4.196M $20.00K
YoY Change 218.86% 176.39% -99.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.500M $1.848M $1.837M
Total Long-Term Liabilities $3.688M $4.196M $20.00K
Total Liabilities $6.188M $6.044M $1.854M
YoY Change 50.33% 58.93% -53.07%
SHAREHOLDERS EQUITY
Retained Earnings -$39.46M -$35.94M -$29.19M
YoY Change 58.38%
Common Stock $45.89M $45.13M $610.00
YoY Change 7523378.85% 2.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.433M $9.189M $15.17M
YoY Change
Total Liabilities & Shareholders Equity $12.62M $15.23M $17.02M
YoY Change -44.07% -39.03% 851.01%

Cashflow Statement

Concept 2015 Q1 2014 Q4 2014 Q2
OPERATING ACTIVITIES
Net Income -$3.521M -$2.920M -$3.547M
YoY Change 19.13% 80.6% 1378.73%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$3.000M -$2.520M -$3.070M
YoY Change 49.95% 33.33% 613.95%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $531.6K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 530.0K 4.500M -2.720M
YoY Change -246.99% 91.49% 1331.58%
NET CHANGE
Cash From Operating Activities -3.000M -2.520M -3.070M
Cash From Investing Activities
Cash From Financing Activities 530.0K 4.500M -2.720M
Net Change In Cash -2.470M 1.980M -5.790M
YoY Change 4.61% 330.43% 833.87%
FREE CASH FLOW
Cash From Operating Activities -$3.000M -$2.520M -$3.070M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6137091
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
12313
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6830
CY2013Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1511461
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
610
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
43874119
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-22691468
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
21183261
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24986458
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2013Q4 us-gaap Liabilities
Liabilities
3803197
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6096752
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6096752
CY2013 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
956980
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-2601828
CY2014 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
10187
CY2013 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
7248
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
221049
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-97647
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1644848
CY2013 us-gaap Operating Expenses
OperatingExpenses
2601828
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14155809
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
931461
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
815008
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6002936
CY2014Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1852116
CY2014Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2874977
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1070479
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
616888
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-2955484
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-3547040
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.49
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.63
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6027672
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6054250
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25120948
CY2014 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
41353
CY2015Q1 dei Entity Public Float
EntityPublicFloat
16009719
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24196691
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
234262
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
161436
CY2014Q4 us-gaap Assets Current
AssetsCurrent
15248706
CY2013Q4 us-gaap Assets Current
AssetsCurrent
24430953
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
53023
CY2014Q4 us-gaap Assets
Assets
15301729
CY2014Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1011629
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
697245
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
555505
CY2013Q4 us-gaap Assets
Assets
24986458
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
284915
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
557399
CY2014 us-gaap Interest Expense
InterestExpense
107834
CY2013 us-gaap Interest Expense
InterestExpense
159885
CY2013 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
82000
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-234637
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-13247681
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-2836465
CY2014 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in a federally insured financial institution in excess of federally insured limits. The Company has established guidelines designed to maintain safety and liquidity, has not experienced any losses in such accounts and believes the exposure to significant risk to the cash balance is minimal.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also relies on clinical research organizations (&#8220;CROs&#8221;) to manage and recruit patients for its clinical trials.&nbsp;&nbsp;If these CROs are unable to continue managing the clinical trials, or are unable to recruit the sufficient number of patients, the delays could adversely affect the completion of the trials and the timing of the filing of our new drug application with the U.S. Food and Drug Administration (&#8220;FDA&#8221;).</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company relies on third-party manufacturers for the production of its drug candidate. If the third-party manufacturers are unable to continue manufacturing the Company&#8217;s drug candidate, or if the Company loses one of its sole source suppliers used in its manufacturing processes, the Company may not be able to meet clinical trial supply demand for its product candidate and the development of the product candidate could be materially and adversely affected. </p></div>
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-19659354
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
145966
CY2013 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
18225166
CY2013 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
187000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1102087
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1522
CY2014 evok Fair Value Of Warrants Issued
FairValueOfWarrantsIssued
108122
CY2014 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
12.00
CY2014 evok Offering Cost
OfferingCost
3859052
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
1102087
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
145966
CY2014 us-gaap Paid In Kind Interest
PaidInKindInterest
59982
CY2013 us-gaap Paid In Kind Interest
PaidInKindInterest
23261
CY2014 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-5483
CY2013 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-6830
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
287503
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
234262
CY2013 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
555505
CY2014 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
866560
CY2014 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
4500000
CY2013 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
2000000
CY2014 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
3000000
CY2014 us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
82685
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
42875
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25120948
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1460190
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
27120948
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-10040882
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
24080678
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
116013
CY2014 us-gaap Interest Paid
InterestPaid
58790
CY2013 us-gaap Interest Paid
InterestPaid
128875
CY2013 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
49000
CY2013 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
18225166
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
327905
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-11501072
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3040270
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
730750
CY2014 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. </p></div>
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.76
CY2014 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.7719
CY2014 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.0000
CY2014Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
108122
CY2014 evok Reverse Stock Split Approved Date
ReverseStockSplitApprovedDate
2013-08-29
CY2014 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2014Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
138000
CY2014 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
70625
CY2013 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
103750
CY2014 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0217
CY2014 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P10Y
CY2014 evok Class Of Warrant Or Right Exercised In Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedInPeriodWeightedAverageExercisePrice
7.50
CY2014Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
16.73
CY2013 evok Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P5Y1M17D
CY2013Q3 evok Warrants To Purchase Common Stock
WarrantsToPurchaseCommonStock
22000
CY2014Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
108122
CY2013Q4 evok Underwriter Discount Commission And Other Offering Expenses
UnderwriterDiscountCommissionAndOtherOfferingExpenses
3900000
CY2013Q4 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
25100000
CY2014 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2007-01-29
CY2013 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
One-for-five
CY2014 evok Stockholder Equity Reverse Stock Split Effective Date
StockholderEquityReverseStockSplitEffectiveDate
2013-08-30
CY2014Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
436375
CY2014Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2433505
CY2014Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2119935
CY2014Q4 evok Long Term Debt Minimum Payments
LongTermDebtMinimumPayments
4989815
CY2014 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
489815
CY2014Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
4500000
CY2014Q4 evok Debt Instrument Carrying Amount1
DebtInstrumentCarryingAmount1
4391878
CY2014 evok Lease Commencement Date
LeaseCommencementDate
December 1, 2013
CY2014 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2015-12-31
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
81086
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
8886
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
12313
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
6830
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
93399
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
CY2014 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2014-09-24
CY2014 invest Investment Warrants Expiration Date
InvestmentWarrantsExpirationDate
2018-09-24
CY2013Q3 evok Warrants To Purchase Convertible Preferred Stock
WarrantsToPurchaseConvertiblePreferredStock
110000
CY2014 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote. The holders of the common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors of the Company.
CY2014 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2013Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
106000
CY2014 evok Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
22881
CY2014 evok Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
10000
CY2014Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
118881
CY2013Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
18.20
CY2014 evok Class Of Warrant Or Right Issued In Period Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedInPeriodWeightedAverageExercisePrice
5.90
CY2014 evok Class Of Warrant Or Right Issued Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualTerm
P10Y
CY2014 evok Class Of Warrant Or Right Exercised Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualTerm
P3Y1M6D
CY2014 evok Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P5Y4M6D
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
624750
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
64000
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
5250
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
683500
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
683500
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
259081
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.61
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.65
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.29
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.67
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.67
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.47
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M28D
CY2014 evok Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted
P9Y4M6D
CY2014 evok Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Exercised
P2Y8M12D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y5M12D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y5M12D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y7M24D
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
869490
CY2014 evok Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Options Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueOptionsExercised
33810
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
649000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
649000
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
631231
CY2014 evok Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Date Intrinsic Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingDateIntrinsicValue
5.90
CY2013 evok Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Date Intrinsic Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingDateIntrinsicValue
7.45
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
33810
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
534210
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
173791
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
424419
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
8.84
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
7.96
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
9.02
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.33
CY2014 evok Stock Issued During Period Shares Employee Stock Purchase Plan
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlan
7294
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1102087
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
145966
CY2014Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2323000
CY2014 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y3M26D
CY2014Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1043457
CY2013Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
769250
CY2014 evok Minimum Age Of Employee To Participate In Defined Benefit Plan
MinimumAgeOfEmployeeToParticipateInDefinedBenefitPlan
21
CY2014 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2014Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2013Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2014 evok Income Tax Examination Period
IncomeTaxExaminationPeriod
Beginning 2007 to date
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.016
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.025
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.058
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.058
CY2014 evok Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
0.050
CY2013 evok Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
0.043
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
-0.412
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
-0.395
CY2014 evok Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation And Other Permanent Items
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationAndOtherPermanentItems
-0.020
CY2013 evok Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation And Other Permanent Items
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationAndOtherPermanentItems
-0.021
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13200000
CY2014 evok Cumulative Minimum Change In Ownership Percentage For Limitation On Utilization Of Net Operating Loss Carry Forwards
CumulativeMinimumChangeInOwnershipPercentageForLimitationOnUtilizationOfNetOperatingLossCarryForwards
0.50
CY2014 evok Cumulative Change In Ownership Period
CumulativeChangeInOwnershipPeriod
P3Y
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1600000
CY2014Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
317000
CY2013Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
147000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
223000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
67000
CY2014Q4 evok Deferred Tax Assets Tax Accruals And Other
DeferredTaxAssetsTaxAccrualsAndOther
105000
CY2013Q4 evok Deferred Tax Assets Tax Accruals And Other
DeferredTaxAssetsTaxAccrualsAndOther
223000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
645000
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
437000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
645000
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
437000
CY2014Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
22000
CY2013Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
0
CY2013Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
110981
CY2013Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
130846
CY2014Q4 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2176388
CY2014Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
738012
CY2014Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3088373
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
732800
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-3825354
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-2919803
CY2014Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2014Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6065841
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1133375
CY2013Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
944359
CY2013Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
78731
CY2013Q4 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
636423
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1137125
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-493992
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-239871
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1190212
CY2013Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5971236
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
72578
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
406862
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-485904
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
-1616698
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2013Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27

Files In Submission

Name View Source Status
0001564590-15-001287-index-headers.html Edgar Link pending
0001564590-15-001287-index.html Edgar Link pending
0001564590-15-001287.txt Edgar Link pending
0001564590-15-001287-xbrl.zip Edgar Link pending
evok-10k_20141231.htm Edgar Link pending
evok-20141231.xml Edgar Link completed
evok-20141231.xsd Edgar Link pending
evok-20141231_cal.xml Edgar Link unprocessable
evok-20141231_def.xml Edgar Link unprocessable
evok-20141231_lab.xml Edgar Link unprocessable
evok-20141231_pre.xml Edgar Link unprocessable
evok-ex231_201412316.htm Edgar Link pending
evok-ex311_201412317.htm Edgar Link pending
evok-ex312_201412318.htm Edgar Link pending
evok-ex321_201412319.htm Edgar Link pending
evok-ex322_2014123110.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g201503041925238122636.jpg Edgar Link pending
g201503041925271242637.jpg Edgar Link pending
g201503041925336712638.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending